Taken together, our studies suggest that the immunogenic properties of calreticulin purified from tumor cells [3], [4] must result from co-purification and subsequent cross-presentation of one or more tumor-derived antigens, rather than a calreticulin-dependent influence on the cross-presentation pathway per se. Here, CALR is linked to neoplasm.